CD8A and non-small cell lung carcinoma: Taken together, these data show that patients with NSCLC whose tumors have low CD8+ T-cell infiltration derive less benefit from current standard ICI-based treatment; therefore, additional treatment strategies are needed to improve outcomes in this population (6, 32).